Incyte Corporation

INCY

US45337C1027

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

Pharmaceuticals

Calendar

2024-05-15 - BofA Securities Health Care Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Incyte Corporation : Is a big change imminent?

October 26, 2023 at 10:00 am EDT

More Strategies

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

53.06 USD

Average target price

73.35 USD

Spread / Average Target

+38.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INCYTE CORPORATION	-8.78%	11.91B
CSL LIMITED	-2.35%	89.08B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.9B
BIOGEN INC.	-13.20%	32.25B
UCB	+54.69%	25.14B
BIOMARIN PHARMACEUTICAL INC.	-16.42%	15.39B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.60%	11.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.82%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.34%	9.03B
INNOVENT BIOLOGICS, INC.	-7.60%	8.62B

Biopharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:41:36 2024-05-13 pm EDT			5-day change	1st Jan Change
57.32 ^USD	+8.02%		+5.92%	-8.78%

08:17pm	Equities Mixed Intraday as Markets Analyze Consumer Inflation Survey	MT
07:50pm	Sector Update: Health Care Stocks Mixed in Afternoon Trading	MT

Equities Mixed Intraday as Markets Analyze Consumer Inflation Survey	02:17pm	MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading	01:50pm	MT
Increasing Short-Term Inflation Expectations Weigh on US Equity Indexes Ahead of Consumer, Producer Prices	01:33pm	MT
US Equity Indexes Trade Mixed as Short-Term Inflation Expectations Increase	01:01pm	MT
Sector Update: Health Care Stocks Decline Pre-Bell Monday	09:32am	MT
Incyte Launches $1.67 Billion Share Repurchase 'Dutch Auction' Tender Offer; to Buy Back $328 Million of Baker Entities' Shares	08:26am	MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07	MT
TD Cowen Adjusts Price Target on Incyte to $80 From $88	May. 01	MT
RBC Capital Adjusts Price Target on Incyte to $60 From $65	May. 01	MT
Piper Sandler Adjusts Price Target on Incyte to $80 From $85	May. 01	MT
Goldman Sachs Adjusts Price Target on Incyte to $60 From $63	May. 01	MT
Leerink Partners Adjusts Price Target on Incyte to $80 From $83, Keeps Outperform Rating	May. 01	MT
Citigroup Adjusts Price Target on Incyte to $80 From $81	May. 01	MT
BMO Capital Adjusts Incyte Price Target to $52 From $56	May. 01	MT
Truist Securities Trims Incyte's Price Target to $83 From $84, Buy Rating Maintained	Apr. 30	MT
Incyte's Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed	Apr. 30	MT
Transcript : Incyte Corporation, Q1 2024 Earnings Call, Apr 30, 2024	Apr. 30
Earnings Flash (INCY) INCYTE Posts Q1 Revenue $880.9M, vs. Street Est of $924.6M	Apr. 30	MT
Earnings Flash (INCY) INCYTE Posts Q1 EPS $0.64, vs. Street Est of $0.83	Apr. 30	MT
Incyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30	CI
Incyte Corporation Maintains Revenue Guidance for 2024	Apr. 30	CI
Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating	Apr. 24	MT
Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call	Apr. 23
Incyte Corporation entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.	Apr. 22	CI
BMO Capital Adjusts Price Target on Incyte to $56 From $64	Apr. 19	MT